Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nuo Therapeutics, Inc.AURX · Entity 7149 | Director · CEO/CFO | August 27, 2026 | August 31, 2026 |
| PLx Pharma Inc.PLXP · Entity 129056 | Acting Chief Financial Officer · 10% owner | June 14, 2017 | June 16, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nuo Therapeutics, Inc.
Report date August 27, 2026 · Filed August 31, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,070,000 |
Last balance in matching sequence
After 2026-08-28 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-08-27 · Purchase · Acquired 789 · Balance 2,062,016 Row 2 · 2026-08-28 · Purchase · Acquired 7,984 · Balance 2,070,000 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.08 to $1.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate transaction with the range set forth herein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.08 to $1.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate transaction with the range set forth herein.
PLx Pharma Inc.
Report date June 14, 2017 · Filed June 16, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 151,913 |
Reported balance
After 2017-06-14 transaction · row 1
1 source rowRow 1 · 2017-06-14 · Purchase · Acquired 32,727 · Balance 151,913 |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $7.50 · Expires 2027-06-14 | Direct | 32,727 |
Reported balance
After 2017-06-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-06-14 · Purchase · Acquired 32,727 · Balance 32,727 F1: Issued pursuant to a private placement in connection with the purchase of common stock in a registered direct offering. |
Filing footnotes · ownership attribution and instrument terms
F1: Issued pursuant to a private placement in connection with the purchase of common stock in a registered direct offering.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 28, 2026 Filed Aug 29, 2026 01:46 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantCommon Stock | 7,984 | $1.09 | $8,694.58 |
DisclosureSEC source: 0001437749-26-029236 · rdgdoc.xml · nonDerivative · entry 2 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,070,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.08 to $1.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate transaction with the range set forth herein. Read SEC document |
| August 28, 2026 Filed Aug 31, 2026 14:29 UTC Amendment | Nuo Therapeutics, Inc. AURX · Entity 7149 | PurchaseCommon Stock | 7,984 | $1.09 | $8,694.58 |
DisclosureSEC source: 0001437749-26-029257 · rdgdoc.xml · nonDerivative · entry 2 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,070,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.08 to $1.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate transaction with the range set forth herein. Read SEC document |
| August 27, 2026 Filed Aug 29, 2026 01:46 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantCommon Stock | 789 | $1.07 | $844.23 |
DisclosureSEC source: 0001437749-26-029236 · rdgdoc.xml · nonDerivative · entry 1 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,062,016 Read SEC document |
| August 27, 2026 Filed Aug 31, 2026 14:29 UTC Amendment | Nuo Therapeutics, Inc. AURX · Entity 7149 | PurchaseCommon Stock | 789 | $1.07 | $844.23 |
DisclosureSEC source: 0001437749-26-029257 · rdgdoc.xml · nonDerivative · entry 1 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,062,016 Read SEC document |
| June 30, 2026 Filed Jul 3, 2026 01:02 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | Exercise / conversionOption to purchase common stock · Derivative | 162,500 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001437749-26-022665 · rdgdoc.xml · derivative · entry 3 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 162,500 shares Expires 2026-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 62,500 options exercisable on 07/01/2016, 50,000 options exercisable on 03/31/2017, and 50,000 options exercisable on 12/31/2017. Read SEC document |
| June 30, 2026 Filed Jul 3, 2026 01:02 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | Tax withholdingCommon Stock | 160,892 | $1.01 | $162,500.92 |
DisclosureSEC source: 0001437749-26-022665 · rdgdoc.xml · nonDerivative · entry 2 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,061,227 F1 · kind: Represents a net exercise of outstanding stock options. The reporting person received 1,608 shares of common stock on the net exercise of option to purchase 162,500 shares of common stock. The issuer withheld 160,892 shares of common stock underlying the option for payment of the exercise price using the closing price of $1.01. F2 · balance_after: Reflects an adjustment of 25,381 shares since the Reporting Person's most recent Form 4 filed June 5, 2026 to correct the amount of securities beneficially owned as a result of the transaction reported in that Form 4. Read SEC document |
| June 30, 2026 Filed Jul 3, 2026 01:02 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | Exercise / conversionCommon Stock | 162,500 | $1.00 | $162,500.00 |
DisclosureSEC source: 0001437749-26-022665 · rdgdoc.xml · nonDerivative · entry 1 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,222,119 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Reflects an adjustment of 25,381 shares since the Reporting Person's most recent Form 4 filed June 5, 2026 to correct the amount of securities beneficially owned as a result of the transaction reported in that Form 4. Read SEC document |
| June 29, 2026 Filed Jul 3, 2026 01:02 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantOption to purchase common stock · Derivative | 125,000 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001437749-26-022665 · rdgdoc.xml · derivative · entry 4 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2036-06-29 F4 · derivative.exercise_date: One third of the options are exercisable as of June 30, 2027 and the balance vest quarterly over the subsequent two years. Read SEC document |
| June 05, 2026 Filed Jun 5, 2026 22:34 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantCommon Stock | 13,245 | $1.10 | $14,505.92 |
DisclosureSEC source: 0001437749-26-019768 · rdgdoc.xml · nonDerivative · entry 1 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,085,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.042 to $1.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate transaction with the range set forth herein. Read SEC document |
| January 01, 2026 Filed Jan 6, 2026 00:25 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | Tax withholdingCommon Stock | 25,381 | $1.97 | $50,000.57 |
DisclosureSEC source: 0001437749-26-000431 · rdgdoc.xml · nonDerivative · entry 2 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,046,374 F1 · kind: Represents a net exercise of outstanding stock options. The reporting person received 99,619 shares of common stock on the net exercise of option to purchase 125,000 shares of common stock. The issuer withheld 25,381 shares of common stock underlying the option for payment of the exercise price using the closing price of $1.97. Read SEC document |
| January 01, 2026 Filed Jan 6, 2026 00:25 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | Exercise / conversionCommon Stock | 125,000 | $0.40 | $50,000.00 |
DisclosureSEC source: 0001437749-26-000431 · rdgdoc.xml · nonDerivative · entry 1 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,071,755 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 28, 2025 Filed Dec 3, 2025 23:13 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | SaleCommon Stock | 200,000 | $1.50 | $300,000.00 |
DisclosureSEC source: 0001437749-25-036821 · rdgdoc.xml · nonDerivative · entry 1 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,946,755 F1 · kind: The transaction reported herein was made in a private transaction to facilitate a personal real estate transaction whereby the shares of common stock acquired constitute "restricted" securities within the meaning of the Securities Act of 1933, as amended. Read SEC document |
| August 01, 2025 Filed Aug 4, 2025 13:09 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | Tax withholdingCommon Stock | 21,313 | $1.74 | $37,084.62 |
DisclosureSEC source: 0001437749-25-024497 · rdgdoc.xml · nonDerivative · entry 3 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,146,755 F1 · kind: Represents a net exercise of outstanding stock options. The reporting person received 71,397 shares of common stock on the net exercise of option to purchase 92,710 shares of common stock. The issuer withheld 21,313 shares of common stock underlying the option for payment of the exercise price using the closing price of $1.74. Read SEC document |
| August 01, 2025 Filed Aug 4, 2025 13:09 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | Exercise / conversionCommon Stock | 92,710 | $0.40 | $37,084.00 |
DisclosureSEC source: 0001437749-25-024497 · rdgdoc.xml · nonDerivative · entry 2 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,168,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2025 Filed Aug 4, 2025 13:09 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | Exercise / conversionCommon Stock | 100,000 | $0.40 | $40,000.00 |
DisclosureSEC source: 0001437749-25-024497 · rdgdoc.xml · nonDerivative · entry 1 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,075,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 23:43 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | SaleCommon Stock | 5,000 | $1.50 | $7,500.00 |
DisclosureSEC source: 0001437749-22-027386 · rdgdoc.xml · nonDerivative · entry 9 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,975,358 F1 · kind: The transactions reported herein were made in private transactions to various persons whereby the shares of common stock acquired constitute "restricted" securities within the meaning of the Securities Act of 1933, as amended. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 23:43 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | SaleCommon Stock | 7,000 | $1.50 | $10,500.00 |
DisclosureSEC source: 0001437749-22-027386 · rdgdoc.xml · nonDerivative · entry 8 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,980,358 F1 · kind: The transactions reported herein were made in private transactions to various persons whereby the shares of common stock acquired constitute "restricted" securities within the meaning of the Securities Act of 1933, as amended. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 23:43 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | SaleCommon Stock | 10,000 | $1.50 | $15,000.00 |
DisclosureSEC source: 0001437749-22-027386 · rdgdoc.xml · nonDerivative · entry 7 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,987,358 F1 · kind: The transactions reported herein were made in private transactions to various persons whereby the shares of common stock acquired constitute "restricted" securities within the meaning of the Securities Act of 1933, as amended. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 23:43 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | SaleCommon Stock | 13,500 | $1.50 | $20,250.00 |
DisclosureSEC source: 0001437749-22-027386 · rdgdoc.xml · nonDerivative · entry 6 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,997,358 F1 · kind: The transactions reported herein were made in private transactions to various persons whereby the shares of common stock acquired constitute "restricted" securities within the meaning of the Securities Act of 1933, as amended. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 23:43 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | SaleCommon Stock | 20,000 | $1.50 | $30,000.00 |
DisclosureSEC source: 0001437749-22-027386 · rdgdoc.xml · nonDerivative · entry 5 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,010,858 F1 · kind: The transactions reported herein were made in private transactions to various persons whereby the shares of common stock acquired constitute "restricted" securities within the meaning of the Securities Act of 1933, as amended. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 23:43 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | SaleCommon Stock | 20,000 | $1.50 | $30,000.00 |
DisclosureSEC source: 0001437749-22-027386 · rdgdoc.xml · nonDerivative · entry 4 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,030,858 F1 · kind: The transactions reported herein were made in private transactions to various persons whereby the shares of common stock acquired constitute "restricted" securities within the meaning of the Securities Act of 1933, as amended. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 23:43 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | SaleCommon Stock | 27,000 | $1.50 | $40,500.00 |
DisclosureSEC source: 0001437749-22-027386 · rdgdoc.xml · nonDerivative · entry 3 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,050,858 F1 · kind: The transactions reported herein were made in private transactions to various persons whereby the shares of common stock acquired constitute "restricted" securities within the meaning of the Securities Act of 1933, as amended. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 23:43 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | SaleCommon Stock | 30,000 | $1.50 | $45,000.00 |
DisclosureSEC source: 0001437749-22-027386 · rdgdoc.xml · nonDerivative · entry 2 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,077,858 F1 · kind: The transactions reported herein were made in private transactions to various persons whereby the shares of common stock acquired constitute "restricted" securities within the meaning of the Securities Act of 1933, as amended. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 23:43 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | SaleCommon Stock | 30,000 | $1.50 | $45,000.00 |
DisclosureSEC source: 0001437749-22-027386 · rdgdoc.xml · nonDerivative · entry 1 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,107,858 F1 · kind: The transactions reported herein were made in private transactions to various persons whereby the shares of common stock acquired constitute "restricted" securities within the meaning of the Securities Act of 1933, as amended. Read SEC document |
| April 29, 2022 Filed May 2, 2022 16:23 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantCommon Stock | 10,532 | $1.00 | $10,532.00 |
DisclosureSEC source: 0001437749-22-010382 · rdgdoc.xml · nonDerivative · entry 1 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,137,858 F1 · date: Transaction approved by Board of Directors of Issuer and Non-Employee Directors Read SEC document |
| March 04, 2022 Filed Apr 27, 2022 01:29 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantOption to Purchase Common Stock · Derivative | 125,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001437749-22-009786 · rdgdoc.xml · derivative · entry 2 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-03-04 Read SEC document |
| March 04, 2022 Filed Apr 27, 2022 01:29 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantOption to Purchase Common Stock · Derivative | 66,672 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001437749-22-009786 · rdgdoc.xml · derivative · entry 1 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,672 Underlying: Common Stock · 66,672 shares Expires 2032-03-04 F1 · date: Granted in settlement of compensation liability for period January 1, 2019 through April 30, 2019 Read SEC document |
| December 30, 2021 Filed Apr 27, 2022 01:25 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | Exercise / conversionWarrants to purchase Common Stock · Derivative | 1,137,635 | $0.00 Strike: $0.20 | $0.00 |
DisclosureSEC source: 0001437749-22-009783 · rdgdoc.xml · derivative · entry 6 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,137,635 shares Expires 2022-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The reported transactions relate to an amendment of the exercise price of outstanding warrants contingent upon the Reporting Person exercising the warrants. As a result, the outstanding warrants were deemed cancelled and modified warrants were issued for the same number of shares of Common Stock, but with a reduced exercise price. Read SEC document |
| December 30, 2021 Filed Apr 27, 2022 01:25 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | Exercise / conversionCommon Stock | 1,137,635 | $0.20 | $227,527.00 |
DisclosureSEC source: 0001437749-22-009783 · rdgdoc.xml · nonDerivative · entry 1 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,127,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2021 Filed Apr 27, 2022 01:25 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | OtherWarrants to purchase Common Stock · Derivative | 160,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001437749-22-009783 · rdgdoc.xml · derivative · entry 5 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,137,635 Underlying: Common Stock · 160,000 shares Expires 2022-01-31 F5 · kind: Transferred to third party for no consideration Read SEC document |
| December 01, 2021 Filed Apr 27, 2022 01:25 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | Disposition to issuerWarrants to purchase Common Stock · Derivative | 397,635 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001437749-22-009783 · rdgdoc.xml · derivative · entry 4 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 397,635 shares Expires 2025-10-05 F1 · kind: Transaction approved by Board of Directors of Issuer and Non-Employee Directors F4 · shares: Cancelled in accordance with Warrant Modification Agreement dated as of 12/01/21 F3 · price: The reported transactions relate to an amendment of the exercise price of outstanding warrants contingent upon the Reporting Person exercising the warrants. As a result, the outstanding warrants were deemed cancelled and modified warrants were issued for the same number of shares of Common Stock, but with a reduced exercise price. Read SEC document |
| December 01, 2021 Filed Apr 27, 2022 01:25 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | Disposition to issuerWarrants to purchase Common Stock · Derivative | 900,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001437749-22-009783 · rdgdoc.xml · derivative · entry 3 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 900,000 shares Expires 2025-10-05 F1 · kind: Transaction approved by Board of Directors of Issuer and Non-Employee Directors F4 · shares: Cancelled in accordance with Warrant Modification Agreement dated as of 12/01/21 F3 · price: The reported transactions relate to an amendment of the exercise price of outstanding warrants contingent upon the Reporting Person exercising the warrants. As a result, the outstanding warrants were deemed cancelled and modified warrants were issued for the same number of shares of Common Stock, but with a reduced exercise price. Read SEC document |
| December 01, 2021 Filed Apr 27, 2022 01:25 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantWarrants to purchase Common Stock · Derivative | 1,297,635 | $0.00 Strike: $0.20 | $0.00 |
DisclosureSEC source: 0001437749-22-009783 · rdgdoc.xml · derivative · entry 2 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,297,635 Underlying: Common Stock · 1,297,635 shares Expires 2022-01-31 F1 · kind: Transaction approved by Board of Directors of Issuer and Non-Employee Directors F2 · shares: Acquired in accordance with Warrant Modification Agreement dated as of 12/01/21 F3 · price: The reported transactions relate to an amendment of the exercise price of outstanding warrants contingent upon the Reporting Person exercising the warrants. As a result, the outstanding warrants were deemed cancelled and modified warrants were issued for the same number of shares of Common Stock, but with a reduced exercise price. Read SEC document |
| October 05, 2020 Filed Apr 27, 2022 01:22 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantWarrants to purchase Common Stock · Derivative | 900,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001437749-22-009780 · rdgdoc.xml · derivative · entry 6 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900,000 Underlying: Common Stock · 900,000 shares Expires 2025-10-05 F1 · kind: Transaction approved by Board of Directors of Issuer and Non-Employee Directors F9 · shares: Compensation warrants acquired in accordance with Recapitalization Agreement Schedule dated as of October 5, 2020 Read SEC document |
| October 05, 2020 Filed Apr 27, 2022 01:22 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | Disposition to issuerWarrants to purchase Common Stock · Derivative | 45,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001437749-22-009780 · rdgdoc.xml · derivative · entry 5 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires not disclosed F1 · kind: Transaction approved by Board of Directors of Issuer and Non-Employee Directors F7 · shares: Cancelled in accordance with Recapitalization Agreement Schedule dated as of October 5, 2020 F6 · price: The reported transactions involved a recapitalization resulting in the deemed cancellation of the "old" warrants and the deemed grant of "replacement" warrants. F8 · derivative.exercise_date: Originally exercisable on 11/15/19 and 12/06/19, with expirations of 11/15/24 and 12/06/24, respectively, for 15,000 shares and 30,000 shares F8 · derivative.expiration_date: Originally exercisable on 11/15/19 and 12/06/19, with expirations of 11/15/24 and 12/06/24, respectively, for 15,000 shares and 30,000 shares Read SEC document |
| October 05, 2020 Filed Apr 27, 2022 01:22 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantWarrants to purchase Common Stock · Derivative | 397,635 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001437749-22-009780 · rdgdoc.xml · derivative · entry 4 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 397,635 Underlying: Common Stock · 397,635 shares Expires 2025-10-05 F1 · kind: Transaction approved by Board of Directors of Issuer and Non-Employee Directors F5 · shares: Acquired in accordance with Recapitalization Agreement Schedule dated as of October 5, 2020 F6 · price: The reported transactions involved a recapitalization resulting in the deemed cancellation of the "old" warrants and the deemed grant of "replacement" warrants. Read SEC document |
| October 05, 2020 Filed Apr 27, 2022 01:22 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantCommon Stock | 50,000 | $0.40 | $20,000.00 |
DisclosureSEC source: 0001437749-22-009780 · rdgdoc.xml · nonDerivative · entry 3 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 989,691 F1 · kind: Transaction approved by Board of Directors of Issuer and Non-Employee Directors F4 · shares: Purchase shares acquired in accordance with Recapitalization Agreement Schedule dated as of October 5, 2020 Read SEC document |
| October 05, 2020 Filed Apr 27, 2022 01:22 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantCommon Stock | 82,545 | $0.40 | $33,018.00 |
DisclosureSEC source: 0001437749-22-009780 · rdgdoc.xml · nonDerivative · entry 2 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 939,691 F1 · kind: Transaction approved by Board of Directors of Issuer and Non-Employee Directors F3 · shares: Conversion shares acquired in accordance with Recapitalization Agreement Schedule dated as of October 5, 2020 Read SEC document |
| October 05, 2020 Filed Apr 27, 2022 01:22 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantCommon Stock | 300,000 | $0.40 | $120,000.00 |
DisclosureSEC source: 0001437749-22-009780 · rdgdoc.xml · nonDerivative · entry 1 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 857,146 F1 · kind: Transaction approved by Board of Directors of Issuer and Non-Employee Directors F2 · shares: Compensation shares acquired in accordance with Recapitalization Agreement Schedule dated as of October 5, 2020 Read SEC document |
| December 06, 2019 Filed Apr 27, 2022 01:18 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantWarrants to purchase Common Stock · Derivative | 30,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001437749-22-009776 · rdgdoc.xml · derivative · entry 2 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 30,000 shares Expires 2024-12-06 F1 · kind: Transaction approved by Board of Directors of Issuer and Non-Employee Directors F2 · shares: Acquired in connection with Note Purchase Agreement dated as of November 15, 2019 Read SEC document |
| November 15, 2019 Filed Apr 27, 2022 01:18 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantWarrants to purchase Common Stock · Derivative | 15,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001437749-22-009776 · rdgdoc.xml · derivative · entry 1 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2024-11-15 F1 · kind: Transaction approved by Board of Directors of Issuer and Non-Employee Directors F2 · shares: Acquired in connection with Note Purchase Agreement dated as of November 15, 2019 Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 17:04 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantOption to Purchase Common Stock · Derivative | 125,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001091596-19-000005 · primary_doc.xml · derivative · entry 1 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: COMMON STOCK · 125,000 shares Expires 2026-01-01 Read SEC document |
| December 31, 2018 Filed Jan 6, 2026 00:25 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | Exercise / conversionOption to purchase common stock · Derivative | 125,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001437749-26-000431 · rdgdoc.xml · derivative · entry 3 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires 2026-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 20:00 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantOption to Purchase Common Stock · Derivative | 192,710 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001605411-18-000003 · primary_doc.xml · derivative · entry 1 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,710 Underlying: COMMON STOCK · 192,710 shares Expires 2025-08-09 Read SEC document |
| August 09, 2018 Filed Aug 4, 2025 13:09 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | Exercise / conversionOption to purchase common stock · Derivative | 192,710 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001437749-25-024497 · rdgdoc.xml · derivative · entry 4 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 192,710 shares Expires 2025-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 19:39 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | PurchaseCOMMON STOCK | 247,500 | $0.22 | $54,994.50 |
DisclosureSEC source: 0001674752-17-000002 · primary_doc.xml · nonDerivative · entry 1 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO, CFO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 557,146 F1 · ownership.direct: Includes shares held jointly with spouse and shares held in IRA. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 14:14 UTC | PLx Pharma Inc. PLXP · Entity 129056 | PurchaseWarrant · Derivative | 32,727 | Not disclosed Strike: $7.50 | Not disclosed |
DisclosureSEC source: 0001313516-17-000001 · primary_doc.xml · derivative · entry 2 JORDEN DAVID EMERSON · CIK 0001313516 · Acting Chief Financial Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,727 Underlying: Common Stock · 32,727 shares Expires 2027-06-14 F1 · price: Issued pursuant to a private placement in connection with the purchase of common stock in a registered direct offering. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 14:14 UTC | PLx Pharma Inc. PLXP · Entity 129056 | PurchaseCommon Stock | 32,727 | $6.88 | $224,998.13 |
DisclosureSEC source: 0001313516-17-000001 · primary_doc.xml · nonDerivative · entry 1 JORDEN DAVID EMERSON · CIK 0001313516 · Acting Chief Financial Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,913 Read SEC document |
| April 19, 2017 Filed Apr 20, 2017 21:16 UTC | PLx Pharma Inc. PLXP · Entity 129056 | GrantOptions · Derivative | 33,753 | $0.00 Strike: $12.44 | $0.00 |
DisclosureSEC source: 0001144204-17-021382 · v464780_4.xml · derivative · entry 2 JORDEN DAVID EMERSON · CIK 0001313516 · Acting Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,753 Underlying: Common Stock · 33,753 shares Expires 2025-07-22 F2 · shares: Received in connection with the Merger in exchange for an employee stock option to buy 42,857 shares of PLx Opco Inc. common stock for $9.80 per share. Read SEC document |
| April 19, 2017 Filed Apr 20, 2017 21:16 UTC | PLx Pharma Inc. PLXP · Entity 129056 | GrantCommon Stock | 119,186 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001144204-17-021382 · v464780_4.xml · nonDerivative · entry 1 JORDEN DAVID EMERSON · CIK 0001313516 · Acting Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,186 F1 · price: Received in exchange for 151,336 shares of common stock of PLx Opco Inc. (formerly PLx Pharma Inc.) in connection with the merger (the "Merger") of PLx Opco Inc. with a wholly owned subsidiary of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.